San Diego, CA, United States of America

Haiyan Tao

This inventor holds 2 USPTO granted patents. Top assignee: Orphagen Pharmaceuticals. Active years: 2025-2026.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Haiyan Tao: Innovator in Inflammatory Disease and Male Contraception

Introduction

Haiyan Tao is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for inflammatory diseases and male contraception. His innovative work has led to the creation of a patent that addresses critical health issues.

Latest Patents

Haiyan Tao holds a patent for "RAR-α compounds for inflammatory disease and male contraception." This patent includes modulators of retinoid acid receptor-alpha (RARα) of formula (I), along with pharmaceutical compositions and methods related to these compounds. His work in this area is crucial for advancing treatment options.

Career Highlights

Tao is associated with Orphagen Pharmaceuticals, where he applies his expertise in pharmaceutical development. His role at the company allows him to focus on innovative solutions that can improve patient outcomes. With 1 patent to his name, he has established himself as a valuable contributor to the field.

Collaborations

Throughout his career, Haiyan Tao has collaborated with notable colleagues, including Raj Kumar Raheja and Scott Thacher. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Haiyan Tao's contributions to the pharmaceutical industry, particularly in the realm of inflammatory diseases and male contraception, highlight his innovative spirit and dedication to improving health outcomes. His work continues to pave the way for future advancements in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…